Results 151 to 160 of about 13,380 (189)

Long-Term Therapy with Eculizumab Biosimilar in Patients with Atypical Haemolytic Uraemic Syndrome: Outcomes of a Prospective Observational Study.

Nephron
Kotenko O, Kozlovskaya N, Emirova K, Muzurov A, Moiseev S, Konakova I, Shavkin A, Makarova T, Gazizulina M, Vinogradov V, Ivanova E, Demyanova K, Korotchaeva Y, Proshina T, Melnikova Y, Рoladova L, Mazur Y, Markova O, Borozinets A.   +18 more
europepmc   +1 more source

Atypical Hemolytic Uremic Syndrome in Children and Adults With the Hot Spot C3 Gene Variant p.Arg161Trp. [PDF]

Kidney Int Rep
Ter Steeg L, Bouwmeester RN, Ter Avest M, Bemelman FJ, Bouts AHM, Bredewold OW, Dorresteijn E, Eijgelsheim M, Engels FAPT, Gracchi V, Heine RT, Keijzer-Veen MG, van de Logt AE, van der Meijden WAG, van Rooij RWG, Severs D, Timmermans SAMEG, van Zuilen AD, Michels MAHM, Wijnsma KL, van den Heuvel LPWJ, Wetzels JFM, Duineveld C, van de Kar NCAJ.   +23 more
europepmc   +1 more source

Eculizumab☆

Reactions Weekly, 2010
In deep review on eculizumab pharmacology and ...
CATALDI, MAURO, A. Cavaccini
core   +4 more sources

Placental Disposition of Eculizumab, C5 and C5-Eculizumab in Two Pregnancies of a Woman With Paroxysmal Nocturnal Haemoglobinuria

British Journal of Clinical Pharmacology, 2021
Contains fulltext : 232079.pdf (Publisher’s version ) (Open Access)Eculizumab is known to cross the placenta to a limited degree, but recently therapeutic drug levels in cord blood were found in a single case.
Saskia Langemeijer, Elena B Volokhina, Gaby A M Eliesen   +2 more
exaly   +2 more sources

Eculizumab Treatment During Pregnancy Does Not Affect the Complement System Activity of the Newborn

Immunobiology, 2015
Eculizumab is a humanized IgG2/4 chimeric anti-complement C5 antibody used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome.
Vedran Stefanovic, Ole-Lars Brekke, Randi Fykse Hallstensen   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Eculizumab

Reactions Weekly
Stephanie J. Phelps, Tracy M. Hagemann, Kelley R. Lee   +2 more
  +11 more sources

Eculizumab

American Journal of Health-System Pharmacy, 2008
The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of eculizumab are reviewed.Eculizumab, a recombinant, humanized, monoclonal, immunoglobulin G antibody produced from murine myeloma cells, is the first agent to be approved for labeling by the Food and Drug ...
openaire   +2 more sources

Eculizumab

Reactions Weekly, 2023
  +7 more sources

Eculizumab

Reactions Weekly, 2018
  +6 more sources